Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025BloodOpen Access

Outcome of children and adolescents with newly diagnosed T-cell acute lymphoblastic leukemia: Results of DFCI ALL consortium protocol 16-001

View Full Paper
Ask AI
Bookmark
Share

Authors

MBMelissa BurnsVKVictoria KochSCSarah M. Cronholm

Discussion

Loading...

Member takes

Overview

Results show favorable outcomes for T-ALL in children treated with multiagent induction chemotherapy, indicating effective prognostic approaches.

Key Points

  • To assess the outcomes for children and adolescents with T-cell acute lymphoblastic leukemia (T-ALL) on DFCI ALL Consortium Protocol 16-001.
  • Children aged 1 to 21 with T-ALL received induction chemotherapy including doxorubicin and dexamethasone.
  • Patients were classified by risk based on biology, with specific treatments based on their classification.
  • Minimal residual disease (MRD) was evaluated using next generation sequencing.
  • Among 86 patients, 76 (91.6%) achieved complete remission (CR).
  • Four-year event-free survival (EFS) and overall survival (OS) were 84.8% and 91.5%, respectively.
  • Patients with low MRD at treatment points had significantly improved outcomes.

Cite This Study

Burns et al. (2025) studied this question.

synapsesocial.com/papers/69362f3a4fa91c937236d400https://doi.org/10.1182/blood-2025-644
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Results in pediatric T-ALL patients treated in trial AIEOP-BFM ALL 2009: Prognostic factors in the context of modern risk-adapted therapy2025
  2. 2Results in pediatric T‐ALL patients treated in trial AIEOP‐BFM ALL 2009: Prognostic factors in the context of modern risk‐adapted therapy2025
  3. 3Clinical characteristics and outcomes of children with T-cell acute lymphoblastic leukemia harboring ABL-class fusions: A report from the ponte di legno consortium2025 · 1 citations
  4. 4Significance of immunophenotypic, cytogenetic, and molecular markers in adult patients with T-cell lymphoblastic leukemia2024 · 1 citations
  5. 5Risk-adjusted therapy of acute lymphoblastic leukemia can decrease treatment burden and improve survival: treatment results of 2169 unselected pediatric and adolescent patients enrolled in the trial ALL-BFM 952008 · 616 citations